The estimated Net Worth of Russ Hawkinson is at least $1.4 Tisíc dollars as of 8 December 2020. Mr Hawkinson owns over 238 units of Silverback Therapeutics stock worth over $1,397 and over the last 4 years he sold SBTX stock worth over $0.
Mr has made over 1 trades of the Silverback Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 238 units of SBTX stock worth $4,998 on 8 December 2020.
The largest trade he's ever made was buying 238 units of Silverback Therapeutics stock on 8 December 2020 worth over $4,998. On average, Mr trades about 60 units every 0 days since 2020. As of 8 December 2020 he still owns at least 238 units of Silverback Therapeutics stock.
You can see the complete history of Mr Hawkinson stock trades at the bottom of the page.
Russ Hawkinson is the Sr. VP of Fin. at Silverback Therapeutics.
Russ's mailing address filed with the SEC is C/O SILVERBACK THERAPEUTICS, INC., 500 FAIRVIEW AVENUE N, SUITE 600, SEATTLE, WA, 98109.
Over the last 6 years, insiders at Silverback Therapeutics have traded over $0 worth of Silverback Therapeutics stock and bought 2,785,936 units worth $58,491,063 . The most active insiders traders include Peter A. Thompson, Thilo Schroeder a Advisors Llc Orbi Med Capit.... On average, Silverback Therapeutics executives and independent directors trade stock every 60 days with the average trade being worth of $1,681,567. The most recent stock trade was executed by Laura Shawver on 5 August 2022, trading 78,740 units of SBTX stock currently worth $100,000.
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Silverback Therapeutics executives and other stock owners filed with the SEC include: